EFFECTS OF SHORT-TERM AND LONG-TERM ADMINISTRATION OF NIFEDIPINE ON SERUM-LIPOPROTEIN METABOLISM IN PATIENTS WITH MILD HYPERTENSION

被引:1
作者
SASAKI, J
ARAKAWA, K
机构
[1] Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, 814-01, 45-1, 7-chome Nanakuma, Jonan-ku
关键词
HYPERTENSION; NIFEDIPINE; LIPIDS; LIPOPROTEINS; APOLIPOPROTEINS;
D O I
10.1007/BF02018313
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of short-and long-term administration of nifedipine on serum lipids, lipoproteins, and apolipoproteins (apo) were studied. Administration of nifedipine capsule for 4 months significantly decreased triglycerides and increased the HDL2 cholesterol and the HDL2/HDL3 cholesterol ratio. No significant changes in serum lipids and lipoproteins were observed during short-term therapy with slow-release nifedipine tablets. Following administration of tablets for 24 months, the LDL/HDL cholesterol ratio, apo B, and apo B/apo A-I ratio increased at 12 months, but reverted to baseline values at 24 months. Apo E levels were decreased significantly at 24 months. No significant changes were noted in total cholesterol, triglyceride, HDL cholesterol, HDL2,3 cholesterol, apo A-I, apo A-II, apo C-II, or apo C-III levels during long-term therapy with slow-release nifedipine tablets. These results indicate that nifedipine has a neutral or even favorable effect on lipoprotein metabolism. However, a prospective well-controlled study would be required to finally establish this effect. This finding strengthens the indications for using nifedipine as a first-line drug in the long-term treatment of hypertension.
引用
收藏
页码:1033 / 1036
页数:4
相关论文
共 16 条
[1]  
Olivari M.J., Bartorelli C., Polsese A., Et al., Treatment of hypertension with nifedipine, a calcium antagonistic agent, Circulation, 59, pp. 1059-1062, (1979)
[2]  
Henry P.D., Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem, Am. J Cardiol, 46, pp. 1047-1058, (1980)
[3]  
Hugenholtz P.G., Michels H.R., Serruys P.W., Brower P.W., Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia, Am J Cardiol, 47, pp. 163-173, (1981)
[4]  
Weidmann P., Uehlinger D.E., Gerber A., Antihypertensive treatment and serum lipoproteins, J Hypertens, 3, pp. 297-306, (1985)
[5]  
Vessby B., Abelin J., Finnson M., Et al., Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism, Curr Ther Res, 33, pp. 1075-1080, (1983)
[6]  
Ohman K.P., Weiner L., von Schenck H., Karlberg B.E., Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension, Eur J Clin Pharmacol, 29, pp. 149-154, (1985)
[7]  
Pasanisi F., Ferrara A.L., Iovine C., Mancini M., Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients, Curr Ther Res, 39, pp. 894-899, (1986)
[8]  
Lehtonen A., Tanskanen A., Lehto H., Jarvensiven P., The effect of nifedipine on plasma lipids in patients with essential hypertension, Int J Clin Pharmacol Ther Toxicol, 24, pp. 357-358, (1986)
[9]  
Schulte K.L., Meyer-Sabllek W.A., Haertenberger A., Et al., Antihypertensive and metabolic effects of diltiazem and nifedipine, Hypertension, 8, pp. 859-865, (1986)
[10]  
Sasaki J., Arakawa K., Effect of nidedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension, Curr Ther Res, 41, pp. 845-851, (1987)